Daejeon, South Korea

Yong Zu Kim

USPTO Granted Patents = 30 

 

 

Average Co-Inventor Count = 12.2

ph-index = 8

Forward Citations = 120(Granted Patents)


Location History:

  • Daejon, KR (2002)
  • Daejeon, KR (2012 - 2024)

Company Filing History:


Years Active: 2002-2025

Loading Chart...
Loading Chart...
Loading Chart...
30 patents (USPTO):

Title: Yong Zu Kim: A Pioneer in Antibody-Drug Conjugate Innovations

Introduction

Yong Zu Kim, a distinguished inventor based in Daejeon, South Korea, holds an impressive portfolio with 27 patents to his name. His contributions to the field of biotechnology, particularly in antibody-drug conjugates (ADCs), have been pivotal in advancing therapeutic techniques.

Latest Patents

Among his latest innovations, Yong Zu Kim has developed antibody-drug conjugates featuring branched linkers. These conjugates improve the delivery and efficacy of active agents by strategically linking them to antibodies through branched linkers that may include a polyethylene glycol moiety. Furthermore, his work on anti-CD19 antibody drug conjugates highlights the versatility of ADCs, allowing for the development of therapeutic modalities that are crucial in treating various diseases. This invention emphasizes the specificity of monoclonal antibodies in binding to CD19, offering researchers and clinicians a robust method for therapeutic, diagnostic, and prophylactic applications.

Career Highlights

Throughout his career, Yong Zu Kim has made significant strides in the biotechnology sector. He has been associated with noteworthy companies, including Legochem Biosciences, Inc. and Legochem Bioscience Ltd. His groundbreaking work has not only led to valuable patents but has also contributed to advancements in drug formulation and delivery systems.

Collaborations

Yong Zu Kim has collaborated with esteemed professionals such as Ho Young Song and Jeiwook Chae, fostering a creative environment that encourages innovation. These collaborations have enabled the sharing of knowledge and expertise, further enhancing the development of novel biotechnological solutions.

Conclusion

Yong Zu Kim continues to be a leading figure in the field of antibody-drug conjugates, as evidenced by his substantial patent portfolio and collaborative efforts. His inventions hold the promise of impactful advancements in medical treatments and diagnostics, reaffirming his status as a prominent inventor in the realm of biotechnological innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…